Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

BeOne Medicines AG

Enrolment target

Start

27 Oct 2023

Confirmed objective response rate (ORR) as assessed by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1.

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.